Originally presented May 23, 2018 as part of the UNC Cancer Network Medical and Surgical Oncology Lecture Series. This Self-Paced, Online Course expired July 4, 2019.
This is a Non-Credit course and does NOT offer continuing education credits.
Presenter
Joshua Zeidner, MD
Assistant Professor
Clinical Research
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill
Acute Myeloid Leukemia (AML): Finally Making Progress?
Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy that affects approximately 20,000 patients each year in the United States. Management of AML has changed little over the last several decades and outcomes remain unsatisfactory. However, recent drug discoveries and approvals show tremendous promise. This presentation will review the current treatment armamentarium of AML highlighting novel concepts and investigational agents in development.
Learning Outcomes
- Discuss pathogenesis/etiology of AML
- Identify diagnostic testing in AML
- Discuss management of AML in younger and older patient populations in the context of recent drug approvals, highlighting some investigational agents in development.
Credits Offered
- 1.0 ANCC (CNE) hours of study.
- 1 ASRT Category A CE Credit
- 1.0 AMA PRA Category 1 Credit™
- General Participation
Requirements
To receive credit for this course, you must:
- Watch a lecture video recording.
- Complete the lecture post test and obtain a passing score of 75% or higher.
- Complete the course evaluation.
- Select credit type.
Estimated course completion time: 1 hour
Disclosures
This activity has been planned and implemented under the sole supervision of the course directors, in association with the UNC Office of Continuing Professional Development (UNC CPD). Dr. Thomas Shea consults for Spectrum Pharma and receives research support from Millennium, Otsuka, GSK, BMS, Novartis and Seattle Genetics. Dr. James Coghill, MD, and CPD staff have no relevant financial relationships with commercial interests as defined by the ACCME.
The speaker, Joshua Zeidner, MD, has received honoraria from Celgene and Tolero (ending in 12/2017) and receives research support from Merck, Millennium Takeda, and Tolero.
Accreditation
This is a Non-Credit course and does NOT offer continuing education credits.
Disclaimer
Please note: This course was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. Questions about personal health should always be referred to a physician or other health care professional.